The goal of this study is to learn if short-term changes in the immune system alter how we process information and experience fear. The main questions it aims to answer are:
Do people who receive typhoid vaccine respond differently than those who receive a placebo saline vaccine? Do people who receive typhoid vaccine experience changes in how they think and feel?
Participants will:
Attend four appointments at the San Francisco VA Health Care System;
Receive typhoid vaccine or placebo at one of the visits;
Have their physiological responding measured while listening to sounds;
Complete questionnaires and psychological tests.

开始日期2024-11-01

申办/合作机构

The University of California, San Francisco

[+3]

NCT06562127 / Not yet recruitingN/AIIT

TBI Rehabilitation and Activation in Veterans (TRAIN-Vets)

This trial will evaluate the impact of a multicomponent program (TBI Rehabilitation and Activation in Veterans; TRAIN-Vets) on improving cognitive function over an 8-month trial period in older Veterans with traumatic brain injury (TBI). Older Veterans with a history of TBI and subjective cognitive complaints will be enrolled and randomly assign to either the TRAIN-Vets intervention (consisting of aquatic-based exercise training, cognitive training, and lifestyle coaching) or the Health Education Control, where they will receive educational materials about brain health and healthy lifestyles.

开始日期2024-11-01

申办/合作机构

Northern California Institute for Research & Education

[+2]

NCT05963568 / Not yet recruiting临床3期IIT

Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)

The overall objective of the Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment II (SMAART-II) is to deploy a hybrid study design to firstly, demonstrate the efficacy of a polypill (Polycap ®) containing fixed doses of antihypertensives, a statin, and antiplatelet therapy taken as two capsules, once daily orally in reducing composite vascular risk over 24 months vs. usual care among 500 recent stroke patients encountered at 12 hospitals in Ghana. Secondly, SMAART II seeks to develop an implementation strategy for routine integration and policy adoption of this polypill for post-stroke cardiovascular risk reduction in an under-resourced system burdened by suboptimal care and outcomes.

开始日期2024-09-01

申办/合作机构

Northern California Institute for Research & Education

100 项与 Northern California Institute for Research & Education 相关的临床结果

登录后查看更多信息

0 项与 Northern California Institute for Research & Education 相关的专利（医药）

登录后查看更多信息

191

项与 Northern California Institute for Research & Education 相关的文献（医药）

2024-09-23·JAMA internal medicine

Deprescribing of Antihypertensive Medications and Cognitive Function in Nursing Home Residents.

Article

作者: Deardorff, W James ; Graham, Laura A ; Dave, Chintan V ; Odden, Michelle C ; Steinman, Michael A ; Abdel Magid, Hoda S ; Growdon, Matthew E ; Jing, Bocheng ; Liu, Xiaojuan ; Boscardin, W John ; Fung, Kathy ; Li, Yongmei ; Lee, Sei J ; Liu, Christine K

ImportanceAntihypertensive medication deprescribing is common among nursing home residents, yet its association with cognitive decline remains uncertain.ObjectiveTo investigate the association of deprescribing antihypertensive medication with changes in cognitive function in nursing home residents.Design, Setting, and ParticipantsThis cohort study using a target trial emulation approach included VA long-term care residents aged 65 years or older with stays of at least 12 weeks from 2006 to 2019. Residents who were not prescribed antihypertensive medication, with blood pressure greater than 160/90 mm Hg, or with heart failure were excluded. Eligible residents with stable medication use for 4 weeks were classified into deprescribing or stable user groups and followed for 2 years or until death or discharge for intention-to-treat (ITT) analysis. Participants switching treatment groups were censored in the per-protocol analysis. Cognitive function measurements during follow-up were analyzed using an ordinal generalized linear mixed model, adjusting for confounders with inverse probability of treatment weighting. Per-protocol analysis included inverse probability of censoring weighting. Data analyses were performed from May 1, 2023, and July 1, 2024.ExposuresDeprescribing was defined as a reduction in the total number of antihypertensive medications or a decrease in medication dosage by 30%, sustained for a minimum of 2 weeks.Main Outcomes and MeasuresCognitive Function Scale (CFS) was classified as cognitively intact (CFS = 1), mildly impaired (CFS = 2), moderately impaired (CFS = 3), and severely impaired (CFS = 4).ResultsOf 45 183 long-term care residents, 12 644 residents (mean [SD] age 77.7 [8.3] years; 329 [2.6%] females and 12 315 [97.4%] males) and 12 053 residents (mean [SD] age 77.7 [8.3] years; 314 [2.6%] females and 11 739 [97.4%] males) met eligibility for ITT and per-protocol analyses, respectively. At the end of the follow-up, 12.0% of residents had a worsened CFS (higher score) and 7.7% had an improved CFS (lower score) with 10.8% of the deprescribing group and 12.1% of the stable user group showing a worsened CFS score. In the per-protocol analysis, the deprescribing group had a 12% reduction in the odds of progressing to a worse CFS category per 12-week period (odds ratio, 0.88; 95% CI, 0.78-0.99) compared to the stable user group. Among residents with dementia, deprescribing was associated with 16% reduced odds of cognitive decline (odds ratio, 0.84; 95% CI, 0.72-0.98). These patterns remained consistent in the ITT analysis.Conclusions and RelevanceThis cohort study indicates that deprescribing is associated with less cognitive decline in nursing home residents, particularly those with dementia. More data are needed to understand the benefits and harms of antihypertensive deprescribing to inform patient-centered medication management in nursing homes.

2024-09-01·Alzheimer's & Dementia

CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease

Article

作者: Quijano-Rubio, Clara ; Milà-Alomà, Marta ; Warmenhoven, Noëlle ; Vilor-Tejedor, Natalia ; Arenaza-Urquijo, Eider ; Suárez-Calvet, Marc ; Blennow, Kaj ; Ortiz-Romero, Paula ; Shekari, Mahnaz ; González-Escalante, Armand ; Kollmorgen, Gwendlyn ; Grau-Rivera, Oriol ; López-Martos, David ; Minguillón, Carolina ; Gispert, Juan Domingo ; Sánchez-Benavides, Gonzalo ; Ashton, Nicholas J ; Zetterberg, Henrik ; Palpatzis, Eleni

AbstractINTRODUCTIONWe examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3‐like protein 1 (YKL‐40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD).METHODSA total of 353 CU (mean age 60.9 years) participants were included (mean follow‐up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations.RESULTSHigher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite) rate of change, and better memory and executive outcomes, independently of AD pathology. Higher baseline plasma GFAP was associated with a decline on attention rate of change. Stratified analyses by Aβ status showed that CSF sTREM2 and YKL‐40 were positively associated with executive functioning in amyloid negative (Aβ−) individuals.DISCUSSIONOur results suggest that a TREM2‐mediated microglial response may be associated with better longitudinal cognitive performance.Highlights

Higher cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cell 2 (sTREM2) relates to better longitudinal cognitive performance.

The association between CSF sTREM2 and cognition is independent of Alzheimer's disease (AD) pathology.

Targeting microglial reactivity may be a therapeutic strategy for AD prevention.

2024-08-01·Journal of Investigative Dermatology

Sphingosine-1-Phosphate–Cathelicidin Axis Plays a Pivotal Role in the Development of Cutaneous Squamous Cell Carcinoma

Article

作者: Park, Kyungho ; Arron, Sarah T. ; Nielsen-Scott, Anna L. ; Mauro, Theodora M. ; Nielsen-Scott, Anna L ; An, Hahyun ; Elias, Peter M. ; Kang, Seung Goo ; Mainzer, Carine ; Choi, Yerim ; Ann, Hahyun ; Elias, Peter M ; Shin, Kyong-Oh ; Mauro, Theodora M ; Holleran, Walter M. ; Park, Jae-Ho ; Wakefield, Joan S ; Kim, Young-Il ; Wakefield, Joan S. ; Uchida, Yoshikazu ; Park, Soo-Hyun ; Bae, Yoojin ; Hwang, Jin-Taek ; Chae, Seungwoo ; Celli, Anna ; Holleran, Walter M ; Arron, Sarah T

Cutaneous squamous cell carcinoma (cSCC) is a common skin cancer caused by mutagenesis resulting from excess UVR or other types of oxidative stress. These stressors also upregulate the production of a cutaneous innate immune element, cathelicidin antimicrobial peptide (CAMP), through endoplasmic reticulum stress-initiated, sphingosine-1-phosphate (S1P) signaling pathway. Although CAMP has beneficial antimicrobial activities, it also can be proinflammatory and procarcinogenic. We addressed whether and how S1P-induced CAMP production leads to cSCC development. Our study demonstrated that (i) CAMP expression is increased in cSCC cells and skin from patients with cSCC; (ii) S1P levels are elevated in cSCC cells, whereas inhibition of S1P production attenuates CAMP-stimulated cSCC growth; (iii) exogenous CAMP stimulates cSCC but not normal human keratinocyte growth; (iv) blockade of FPRL1 protein, a CAMP receptor, attenuates cSCC growth as well as the growth and invasion of cSCC cells mediated by CAMP into an extracellular matrix-containing fibroblast substrate; (v) FOXP3+ regulatory T-cell (which decreases antitumor immunity) levels increase in cSCC skin; and (vi) CAMP induces endoplasmic reticulum stress in cSCC cells. Together, the endoplasmic reticulum stress-S1P-CAMP axis forms a vicious circle, creating a favorable environment for cSCC development, that is, cSCC growth and invasion impede anticancer immunity.

项与 Northern California Institute for Research & Education 相关的新闻（医药）

2024-06-06

·GlobeNewswire-Health Care

Spectral AI Reaches 50% Enrollment at Burn Centers for U.S. Pivotal Burn Study

Total Patient Enrollment of 90 Towards Overall Target of 240 DALLAS, June 06, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has achieved 50% clinical trial site enrollment at burn centers for its 2024 pivotal study designed to validate the algorithm used by its DeepView™ System for burn indication. This pivotal study, which is targeting enrollment of 240 patients, including both adult and pediatric subjects at multiple burn centers and emergency departments across the U.S., is expected to be the final clinical trial before seeking FDA approval in 2025. The completion of the pivotal study will address two primary objectives. First, the study will validate the standalone performance of the DeepView™ System’s algorithm on an independent dataset, further solidifying its objective utility in clinical practice. Second, the study will compare the efficacy of the DeepView™ System's finalized image processing algorithm against existing clinician assessment, as quantified by clinician judgment annotations. “We are committed to advancing burn care through the implementation of innovative technologies and rigorous clinical research. Our objective is to deliver to healthcare providers the cutting-edge tools they need to enhance their ability to immediately and accurately assess a burn wound’s healing potential,” stated Mary Regan, VP of Medical Affairs at Spectral AI. “We are enthusiastic about the achievement of this enrollment milestone as we aim to demonstrate DeepView’s AI effectiveness in providing accurate wound assessments and timely clinical decision-making for burn injuries.” “As clinicians, our goal is to provide the best possible care for burn patients, utilizing the latest medical advancements and techniques,” said Dr. Kathleen Romanowski, Principal Investigator at one of the clinical trial sites, the UC Davis Firefighters Burn Institute Regional Burn Center. “DeepView's technology has the potential to significantly enhance our ability to assess burn wounds accurately, leading to improved patient outcomes and quality of life.” The Company’s DeepView™ System image processing algorithm utilizes multispectral imaging, trained and tested against a proprietary database of more than 340 billion clinically validated data points, to deliver a rapid and objective assessment that aids healthcare providers in assessing the healing potential of a burn wound. The U.S. pivotal study is currently enrolling patients at several leading burn centers in the U.S., with esteemed Principal Investigators overseeing the research. A list of the burn centers currently enrolled in the Company’s U.S. pivotal study is below. U.S. Clinical Trial Sites Principal InvestigatorArizona Burn Center Valleywise Health Dr. Kevin Foster VCU Health Evans-Haynes Burn Center Dr. Michael Feldman St Christopher’s Stuart J. Hulnick Burn Center Dr. Paul Glat UC Davis Firefighters Burn Institute Regional Burn Center Dr. Kathleen Romanowski Shriners Children's Northern California Neil Reitman Pediatric Burn Institute Dr. Kathleen Romanowski UW Harborview Regional Burn Center Dr. Tam Pham University of Kansas Burnett Burn Center Dr. Dhaval Bhavsar North Carolina Jaycee Burn Center Dr. Booker King SUNY Stony Brook Burn Center Dr. Adam Singer Akron Children’s Hospital Burn Institute Dr. Anjay Khandelwal University of Iowa Burn Treatment Center Dr. Lucy Wibbemeyer The Ohio State Comprehensive Burn Center Dr. Nicole Bernal About Spectral AI Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to change the current standard of care, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com. Forward Looking Statements Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Contacts: Investors: The Equity Group Devin Sullivan Managing Director dsullivan@equityny.com Conor Rodriguez Analyst crodriguez@equityny.com

临床研究

2024-01-16

·Business Wire

Acquired Gene or Chromosome Alterations Clinical Pipeline Research Report 2023: Analysis of Stages of Development, Segments, Region and Countries, Regulatory Path and Competitive Landscape - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Acquired Gene or Chromosome Alterations Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering. Acquired Gene or Chromosome Alterations Pipeline Report provides comprehensive information about the Acquired Gene or Chromosome Alterations pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. This report offers extensive coverage of Acquired Gene or Chromosome Alterations under development, providing comprehensive insights into pipeline products, major players, developmental activities, clinical trial data, and recent developments in the segment/industry. Acquired Gene or Chromosome Alterations comprises of reagents employed for genetic testing to detect cancer causing/ related alterations, such as; k-ras, BRCA 1+2, Telomerase and HER-2/neu (human epidermal growth factor receptor 2). The report reviews the details of major pipeline products, including product descriptions, licensing and collaboration details, and other developmental activities related to Acquired Gene or Chromosome Alterations. It also lists all the pipeline projects involving major players engaged in the development of Acquired Gene or Chromosome Alterations. Coverage of pipeline products is based on various stages of development, ranging from Early Development to Approved/Issued stages, allowing readers to understand the progress of these products in the pipeline. Key clinical trial data related to ongoing trials specific to pipeline products in the Acquired Gene or Chromosome Alterations segment is provided, offering valuable insights into the clinical development of these products. Reasons to Buy Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Acquired Gene or Chromosome Alterations under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Acquired Gene or Chromosome Alterations Overview 3 Products under Development 3.1 Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development 3.2 Acquired Gene or Chromosome Alterations - Pipeline Products by Territory 3.3 Acquired Gene or Chromosome Alterations - Pipeline Products by Regulatory Path 3.4 Acquired Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date 3.5 Acquired Gene or Chromosome Alterations - Ongoing Clinical Trials 4 Acquired Gene or Chromosome Alterations - Pipeline Products under Development by Companies 4.1 Acquired Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development 4.2 Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development 5 Acquired Gene or Chromosome Alterations Companies and Product Overview 6 Acquired Gene or Chromosome Alterations- Recent Developments 7 Appendix A selection of companies mentioned in this report includes Abital Pharma Pipelines Ltd Admera Health LLC Agena Bioscience Inc Aix-Marseille University Albert Ludwigs University of Freiburg Apteryx Imaging Inc Baruch S. Blumberg Institute Baylor College of Medicine bioMerieux SA Biotype Innovation GmbH Blondin Bioscience, LLC Cardiff Oncology Inc Cepheid Inc Children's Hospital Los Angeles Children's Hospital of Philadelphia China Medical Technologies Inc (Inactive) Chronix Biomedical Inc Columbia University Duke University Empire Genomics LLC Fred Hutchinson Cancer Research Center French National Institute of Health and Medical Research Garvan Institute of Medical Research Gencurix Inc Genetag Technology, Inc Genomic Health Inc GenomicTree Co Ltd German Cancer Research Center H. Lee Moffitt Cancer Center & Research Institute Inc Heali Ltd Hebrew University of Jerusalem Heidelberg Pharma AG Helmholtz Centre for Infection Research Inform Genomics Inc Institute of Cancer Research Interpace Biosciences Inc iTP Biomedica Corp Johns Hopkins University Massachusetts General Hospital Mayo Clinic McGill University MDNA Life Sciences Inc MolecularMD Corp Myriad International GmbH Nel ASA Northern California Institute for Research and Education NucleoBio Inc Ohio State University OmicsWay Corp Oxford Biodynamics Plc Oxford Cancer Biomarkers Ltd Pennsylvania State University Princess Margaret Cancer Centre QuantuMDx Group Ltd Queen's University Belfast Rosetta Genomics Ltd (Inactive) Stanford University Stony Brook University Syamala Srinivasa Life Sciences Pvt. Ltd Telo Genomics Corp The Chinese University of Hong Kong The University of New South Wales press Limited The Walter and Eliza Hall Institute of Medical Research TheraDiag SA Therawis Diagnostics GmbH Thrive Earlier Detection Corp Total Brain Ltd Trinity College Dublin University College London University of California San Diego University of Cambridge University of Central Florida University of Cologne University of Copenhagen University of Hawaii at Manoa University of Montreal University of Rochester University of South Carolina University of Southern California University of Strathclyde University of Sydney University of Texas Medical Branch at Galveston University of Washington Vyant Bio Inc Wistar Institute Yaathum Biotech Pvt Ltd Yale University For more information about this report visit https://www.researchandmarkets.com/r/fb39kc About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

并购

2022-07-12

·PRNewswire

Curaleaf's Select Brand Announces Launch of "The Farmer's Select" Program

Ongoing Series of Product Collaborations With California's Craft Farmers Reflects Company's Commitment to Partnerships with Legacy Growers and Diverse OperatorsLimited-Release Select Elite Live Partnership With Delighted Farms is Select's Second Collaboration WAKEFIELD, Mass., July 12, 2022 /PRNewswire/ -- Curaleaf Holdings, Inc. (CSE: CURA /OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced that its Select brand has launched "The Farmer's Select" program, an ongoing series of limited-edition collaborations with licensed legacy farmers and diverse operators in California. In celebration of launch, Select's second Elite Live collaboration is now available across the state in partnership with Delighted Farms, a state-of-the-art indoor farm managed by a team of legacy California growers. The Farmer's Select The Farmer's Select program reaffirms Curaleaf's commitment to providing premium products to consumers while uplifting smaller craft operators across the Golden State. Select initiated its first Elite Live collaboration in April 2022 with Sonoma Hills Farm, a Sun+Earth certified cannabis farm nestled on 60-acres in Sonoma Valley. The limited-edition product line sold out in under two weeks and the partnership's success empowered Curaleaf to explore more ways to support craft genetics grown by farmers engrained in California's cannabis culture. Select's latest product collaboration transforms Delighted Farms' top-quality, limited-batch cannabis flower into the same Select Elite Live Oil that customers know and love. The limited-edition product line is now available at dispensaries across California in three strains including Napali Sunrise (Sativa), Frozen Gushers (Hybrid) and Gas Pie (Indica). "On behalf of the Select brand, we are proud to launch The Farmer's Select program and reaffirm our commitment to creating an equitable cannabis industry where all can participate and hopefully, partner together to strengthen the industry," said Matt Darin, CEO of Curaleaf. "This one-of-a-kind program not only connects cannabis industry leaders, but it also highlights skills of innovative growers, talented extractors and other vital figures that power California's cannabis ecosystem." "Curaleaf and Select's commitment to providing quality products aligns with Delighted's commitment to producing premium, top-quality cannabis flower that honors the history and cannabis culture of California," said Joshua Pritchard, Founder & CEO of Delighted Farms. "We're excited to introduce our collaboration with Select, and we're happy to help break the stigma of "us versus them" competition in the cannabis community. The spirit of the plant is about sharing and connecting, and partnerships based on quality lift up our industry. We look forward to crafting more premium products in the future." The Select Elite Live Delighted Farms collaboration is now available at dispensaries across California while supplies last. For more information on product availability, visit or visit one of the participating retailers below. Northern California Airfield (San Jose, CA) Bloomerang (San Francisco, CA) Cannabis21+/SDRC (Ukiah, CA) Connected Cannabis Co (Sacramento, San Francisco and Stockton, CA) Haze San Jose (San Jose, CA) High Times (Oakland, Redding, Shasta Lake and Coalinga, CA) Joy Reserve (San Francisco, CA) Kolas/Cloud 9 (Sacramento, CA) Mission Organic (San Francisco, CA) Purple Lotus (San Jose, CA) Redwood Herbal Alliance (Santa Rosa, CA) The Bright Spot (Fairfield, CA) Velvet (Martinez, CA) Vibe by California (Sacramento, Stockton, Ukiah and Redding, CA) Southern California Cannabis21+/SDRC (Palm Desert, CA) Erba Pico (Los Angeles, CA) High Times (Blythe and San Bernardino, CA) Organic Greens Collective (Goleta, CA) Semilla (Sun Valley, CA) The Woods (West Hollywood, CA) Velvet Eagle Rock (Los Angeles, CA) Vibe by California (Palm Springs, CA) Delivery Eaze (CA) Emberz (Southern CA) About Curaleaf Holdings Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. In the United States, Curaleaf currently operates in 22 states with 134 dispensaries, 26 cultivation sites, and employs over 5,700 team members. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit . FORWARD-LOOKING STATEMENTS This media advisory contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", "expects" or, "proposed", "is expected", "intends", "anticipates", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward–looking statements and information concerning the Farmer's Select program and our second Elite Live collaboration with Delighted Farms. Such forward-looking statements and information reflect management's current beliefs and are based on assumptions made by and information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under "Risk Factors and Uncertainties" in the Company's latest annual information form filed March 9, 2022, which is available under the Company's SEDAR profile at , and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward looking statements contained in this press release. The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release. INVESTOR CONTACT Curaleaf Holdings, Inc. Investor Relations [email protected] MEDIA CONTACT Curaleaf Holdings, Inc. Tracy Brady, SVP Corporate Communications [email protected] SOURCE Curaleaf Holdings, Inc.